BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is -10.79% lower on its value in year-to-date trading and has touched a low of $62.88 and a high of $131.95 in the current 52-week trading range. The BMRN stock was last observed hovering at around $74.89 in the last trading session, with the day’s gains setting it 0.54% off its average median price target of $109.00 for the next 12 months. It is also 59.88% off the consensus price target high of $188.00 offered by 25 analysts, but current levels are 5.71% higher than the price target low of $80.00 for the same period.
Currently trading at $75.43, the stock is -28.73% and -35.54% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.07 million and changing 0.72% at the moment leaves the stock -20.87% off its SMA200. BMRN registered 2.36% gain for a year compared to 6-month gain of -16.53%. The firm has a 50-day simple moving average (SMA 50) of $114.86 and a 200-day simple moving average (SMA200) of $100.68.
The stock witnessed a -37.42% loss in the last 1 month and extending the period to 3 months gives it a -29.21%, and is 0.77% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.16% over the week and 3.47% over the month.
BioMarin Pharmaceutical Inc. (BMRN) has around 3001 employees, a market worth around $13.65B and $1.85B in sales. Current P/E ratio is 114.64 and Fwd P/E is 109.16. Profit margin for the company is 6.60%. Distance from 52-week low is 19.96% and -42.83% from its 52-week high. The company has generated returns on investments over the last 12 months (-0.70%).
BioMarin Pharmaceutical Inc. (BMRN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for BioMarin Pharmaceutical Inc. (BMRN) is a “Overweight”. 25 analysts offering their recommendations for the stock have an average rating of 2.20, where 10 rate it as a Hold and 2 think it is a “Overweight”. 13 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
BioMarin Pharmaceutical Inc. is expected to release its quarterly report on 10/22/2020 and quarterly earnings per share for the current quarter are estimated at $1.33 with sales reaching $455.56M over the same period. The EPS is expected to grow by 69.50% this year, but quarterly earnings will post 9.20% year-over-year. Quarterly sales are estimated to shrink -1.20% in year-over-year returns.
BioMarin Pharmaceutical Inc. (BMRN) Top Institutional Holders
726 institutions hold shares in BioMarin Pharmaceutical Inc. (BMRN), with 897.68k shares held by insiders accounting for 0.49% while institutional investors hold 99.80% of the company’s shares. The shares outstanding are 180.73M, and float is at 180.33M with Short Float at 5.52%. Institutions hold 99.30% of the Float.
The top institutional shareholder in the company is Capital Research Global Investors with over 22.07 million shares valued at $2.72 billion. The investor’s holdings represent 12.17% of the BMRN Shares outstanding. As of Jun 29, 2020, the second largest holder is Primecap Management Company with 17.88 million shares valued at $2.21 billion to account for 9.86% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 16.92 million shares representing 9.33% and valued at over $2.09 billion, while Blackrock Inc. holds 8.80% of the shares totaling 15.96 million with a market value of $1.97 billion.
BioMarin Pharmaceutical Inc. (BMRN) Insider Activity
A total of 82 insider transactions have happened at BioMarin Pharmaceutical Inc. (BMRN) in the last six months, with sales accounting for 37 and purchases happening 45 times. The most recent transaction is an insider sale by GREY MICHAEL G, the company’s Director. SEC filings show that GREY MICHAEL G sold 2,500 shares of the company’s common stock on Aug 03 at a price of $120.35 per share for a total of $0.3 million. Following the sale, the insider now owns 42840.0 shares.
BioMarin Pharmaceutical Inc. disclosed in a document filed with the SEC on Jul 20 that FUCHS HENRY J (President, Worldwide R&D) sold a total of 126,389 shares of the company’s common stock. The trade occurred on Jul 20 and was made at $130.00 per share for $16.43 million. Following the transaction, the insider now directly holds 0.1 million shares of the BMRN stock.
Still, SEC filings show that on Jul 13, FUCHS HENRY J (President, Worldwide R&D) disposed off 23,011 shares at an average price of $130.00 for $2.99 million. The insider now directly holds 102,995 shares of BioMarin Pharmaceutical Inc. (BMRN).
BioMarin Pharmaceutical Inc. (BMRN): Who are the competitors?
The company’s main competitors (and peers) include Amicus Therapeutics Inc. (FOLD) that is trading 43.46% up over the past 12 months. Sanofi (SNY) is 17.99% up on the 1-year trading charts. Short interest in the company’s stock has risen 1.46% from the last report on Jul 14, 2020 to stand at a total of 10.09 million short shares sold with a short interest ratio of 10.26.